RE: FACTS and FANTASY15 Feb 2024 00:36
The word used in the 05/22 RNS was ELIGIBLE meaning some qualifying standard to be achieved before entitled to receive various payments whatever they might be. Whilst the period to be used not specified, the term INITIAL could, 20 odd months on, by now have well passed without payment as :
- no revenues/income shown in 2022 AA's
- unlike with the Haleon payment, no reference made in either Interim Statement or recent TU, suggesting 2023 revenues more likely just purely sales related. If, however, the £3.1m included a/some one off receipts unit sales would have been less than probably expected thereby raising other questions
N.B. who is to say the £500K delayed sale into Jan when planned for Dec was not a strategic delay on somebody's part to obviate the triggering of a milestone payment!!
I have no knowledge of Pharma Agreements but for a potentially world busting product a 35/65 split, if that is what it is, ifo Coopers would look generous but who needed who the most - FUM of Coopers I would suggest, as had no commercial operational expertise or infrastructure within than to rely on others which is hardly a good negotiating position to be in. And why the rush to extend the Licence Agreement to 2029 when the existing one still had another 3 years to run and at that time the chance to get a better deal if all had gone swimmingly - do/did Coopers see a good thing and topped up as early as poss. to avoid seeing their position diluted if all took off as everybody hopes for. And you could ask what did FUM have to give up to Haleon i.e lesser terms in return for an up front cash payment which might have, for instance, avoided the need for a further Fund Raise as I imagine will continue to bleed cash during the coming months
All of the above might be seen as pure conjecture but whilst have seemingly got in bed with two industry powerhouses, they being very seasoned and experienced operators could well have taken the biscuit from others who had never been in this position before.
The overall story sounds good, as I hope proves to be the case, but you have to ask yourselves why with all that keeps on coming regarding ever increasing link ups, approvals, forthcoming launches etc why the SP sunk from the 50's to the 20's and now only just back to the early 40's. It could be the MM's playing ducks and drakes but, more likely as I have said before, being wary, until definitively shown otherwise, of the financial viability of Eroxon. After all it is no good having say £100M of sales if your terms with others won't make you a penny or at least a decent return, especially as it is this that will determine the worth/value of any business. As I see it the Jury is still very much out on that one. No doubt the investment wise men/gurus who seem to presently pervade this BB will likely want to tell me I don't know what I am talking about but hey ho I have only tried to apply logic and rationale rather than pump speculation or pure unsubstantiated rhetoric.